SRMS

Across TCGA pan-cancer cohorts, SRMS Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated SRMS data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SRMS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SRMS expression acts as an unfavorable survival marker, although some lineages such as SCLC and SKCM show a favorable association.

BLCA, LUAD, and SCLC are the cancer types where SRMS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.082	0.688	<.001	30	view →
LUAD	OS	Median	II,III,IV	0.111	0.750	<.001	24	view →
SCLC	DFS	Median	All	0.838	0.251	.011	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	6	view →
READ	OS	Median	All	0.281	0.830	.006	3	view →
ESCA	DFS	Median	All	0.233	0.537	.041	3	view →
SKCM	DFS	Median	III,IV	1.000	0.249	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

SRMS–BLCA (OS)

Open the BLCA breakdown →